Lv31
210 积分 2025-08-14 加入
Emerging trends in the global burden of colorectal cancer
1小时前
已完结
Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies
17天前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
17天前
已完结
Preclinical and phase I trials of topoisomerase I inhibitors
22天前
已完结
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
23天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
1个月前
已完结
Fcγ receptors and immunomodulatory antibodies in cancer
3个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
4个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
5个月前
已完结
皖公网安备34019202002308
